The University of Southampton
University of Southampton Institutional Repository

A tale of two CysLTs

A tale of two CysLTs
A tale of two CysLTs
The importance of the cysteinyl-leukotrienes (cysLTs) LTC4, LTD4 and LTE4 as mediators of asthma is now widely recognized [1]. Their biological actions, including bronchoconstriction, microvascular oedema, mucus hypersecretion and eosinophil chemotaxis, are mediated by CysLT type 1 (CysLT1) and type 2 (CysLT2) receptors distinct from those for LTB4, the sole member of a separate branch of the leukotriene family. CysLT1 is the molecular target of the leukotriene receptor antagonists montelukast, pranlukast and zafirlukast that have entered international asthma treatment guidelines since their introduction in many countries in 1997. These drugs do not block CysLT2 and the actions of cysLTs mediated by the type 2 receptor remain poorly defined. Although cys-LT receptor subtypes were first identified pharmacologically, the recent cloning and molecular characterization of both receptors [2-5] represents an important advance in defining their respective roles in airway inflammation. In particular, the ability of the oral CysLT1 antagonists to reduce eosinophilia in the blood and airways of asthmatic patients over a period of weeks [6] points to an important role of cysLTs and CysLT1 receptors in regulating eosinophil migration, proliferation, or apoptosis. The current issue of Clinical & Experimental Allergy contains an intriguing report by Dr Mita and colleagues from the National Sagamihara Hospital in Kanagawa, Japan, indicating that human eosinophils in fact express greater amounts of mRNA for the CysLT2 receptor than for CysLT1[7]. This raises the interesting possibility that the CysLT2 receptor may mediate important aspects of eosinophil behaviour. This review will survey current information on the two cysLT receptor subtypes and examine the evidence for their relative contribution to inflammatory processes.
0954-7894
1660-1664
James, Anna J.
01a53d5d-aef4-4517-b3a9-23d9776fb57f
Sampson, A. P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
James, Anna J.
01a53d5d-aef4-4517-b3a9-23d9776fb57f
Sampson, A. P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60

James, Anna J. and Sampson, A. P. (2001) A tale of two CysLTs. Clinical Exp Allergy, 31 (11), 1660-1664. (doi:10.1046/j.1365-2222.2001.01259.x).

Record type: Editorial

Abstract

The importance of the cysteinyl-leukotrienes (cysLTs) LTC4, LTD4 and LTE4 as mediators of asthma is now widely recognized [1]. Their biological actions, including bronchoconstriction, microvascular oedema, mucus hypersecretion and eosinophil chemotaxis, are mediated by CysLT type 1 (CysLT1) and type 2 (CysLT2) receptors distinct from those for LTB4, the sole member of a separate branch of the leukotriene family. CysLT1 is the molecular target of the leukotriene receptor antagonists montelukast, pranlukast and zafirlukast that have entered international asthma treatment guidelines since their introduction in many countries in 1997. These drugs do not block CysLT2 and the actions of cysLTs mediated by the type 2 receptor remain poorly defined. Although cys-LT receptor subtypes were first identified pharmacologically, the recent cloning and molecular characterization of both receptors [2-5] represents an important advance in defining their respective roles in airway inflammation. In particular, the ability of the oral CysLT1 antagonists to reduce eosinophilia in the blood and airways of asthmatic patients over a period of weeks [6] points to an important role of cysLTs and CysLT1 receptors in regulating eosinophil migration, proliferation, or apoptosis. The current issue of Clinical & Experimental Allergy contains an intriguing report by Dr Mita and colleagues from the National Sagamihara Hospital in Kanagawa, Japan, indicating that human eosinophils in fact express greater amounts of mRNA for the CysLT2 receptor than for CysLT1[7]. This raises the interesting possibility that the CysLT2 receptor may mediate important aspects of eosinophil behaviour. This review will survey current information on the two cysLT receptor subtypes and examine the evidence for their relative contribution to inflammatory processes.

This record has no associated files available for download.

More information

Published date: 1 January 2001

Identifiers

Local EPrints ID: 455373
URI: http://eprints.soton.ac.uk/id/eprint/455373
ISSN: 0954-7894
PURE UUID: d958fac0-0162-4419-80ec-9a9df17308c0
ORCID for A. P. Sampson: ORCID iD orcid.org/0009-0008-9653-8935

Catalogue record

Date deposited: 18 Mar 2022 17:59
Last modified: 17 Mar 2024 02:43

Export record

Altmetrics

Contributors

Author: Anna J. James
Author: A. P. Sampson ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×